The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Antiretroviral Effects on HBV/HIV Co-infection and the Natural History of Liver Disease
1 Division of Infectious Diseases, Denver Health Medical Center, 601 Broadway Street, MC 4000, Denver, CO 80204, USA; Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, CO, USA. Electronic address: David.Wyles@dhha.org.
Abstract
Hepatitis B virus (HBV) coinfection is common in persons with human immunodeficiency virus (HIV) infection, contributing significantly to morbidity and mortality. Many currently used HIV antiretroviral therapy (ART) regimens provide potent anti-HBV activity and it is recommended that HBV-HIV coinfected persons be treated with ART regimens containing tenofovir. ART has multiple benefits, including increasing rates of HBV clearance after initial infection and potent suppression of HBV DNA in chronic infection. Nevertheless, long-term studies have yet to demonstrate a profound positive impact of ART on HBV-related fibrosis progression and development of endstage liver disease.